SPRO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.00

-100%

-0.200

-47.37%

0.00

-100%

-0.180

-28%

0.00

-100%

-0.170

+466.67%

Estimates Revision

The market is revising No Change the revenue expectations for Spero Therapeutics, Inc. (SPRO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 13.33%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-74.36%

In Past 3 Month

Stock Price

Go Up

+13.33%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Spero Therapeutics Inc (SPRO.O) is 4.92, compared to its 5-year average forward P/E of -2.24. For a more detailed relative valuation and DCF analysis to assess Spero Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.24

Current PE

4.92

Overvalued PE

0.02

Undervalued PE

-4.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.13

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.81

Undervalued EV/EBITDA

-3.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.99

Current PS

18.98

Overvalued PS

26.77

Undervalued PS

-2.80

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 486.02% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 486.02% over the last month.

Sold

Bought

SPRO News & Events

Events Timeline

No data

News

9.0

2025-12-19Globenewswire

Spero Therapeutics and GSK Submit NDA for Tebipenem HBr, Triggering $25 Million Milestone Payment

5.0

2025-12-19Newsfilter

Spero Therapeutics and GSK Submit NDA for Tebipenem HBr, Triggering $25M Milestone Payment

5.0

2025-11-28Globenewswire

Spero Therapeutics Grants 90,000 RSUs to New Employee Under 2019 Inducement Plan

People Also Watch

Frequently Asked Questions

What is Spero Therapeutics Inc (SPRO) stock price today?

The current price of SPRO is 2.55 USD — it has decreased -0.78 % in the last trading day.

What is Spero Therapeutics Inc (SPRO)'s business?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

What is the price predicton of SPRO Stock?

Wall Street analysts forecast SPRO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Spero Therapeutics Inc (SPRO)'s revenue for the last quarter?

Spero Therapeutics Inc revenue for the last quarter amounts to 5.44M USD, decreased -59.60 % YoY.

What is Spero Therapeutics Inc (SPRO)'s earnings per share (EPS) for the last quarter?

Spero Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -59.38 % YoY.

What changes have occurred in the market's expectations for Spero Therapeutics Inc (SPRO)'s fundamentals?

How many employees does Spero Therapeutics Inc (SPRO). have?

Spero Therapeutics Inc (SPRO) has 32 emplpoyees as of January 10 2026.

What is Spero Therapeutics Inc (SPRO) market cap?

Today SPRO has the market capitalization of 143.67M USD.